Pfizer Limited has announced a senior management personnel change, with Ms. Aditi Mehta resigning from her position as Category Lead-Vaccines. The pharmaceutical company informed stock exchanges about this development on December 23, 2025, in compliance with regulatory disclosure requirements.

Resignation Details

Ms. Aditi Mehta has tendered her resignation from Pfizer Limited effective January 2, 2026 (close of business). She is leaving the company to pursue opportunities outside Pfizer Limited. Following her resignation, Ms. Mehta will cease to be a Senior Management Personnel of the company from the effective date.

Regulatory Compliance

The company has fulfilled its disclosure obligations under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The resignation letter, as required under SEBI Listing Regulations 2015 and SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, was enclosed with the regulatory filing.

Stock Exchange Communication

Pfizer Limited communicated this personnel change to both major Indian stock exchanges on December 23, 2025. The notification was sent to BSE Limited (Scrip Code: 500680) and The National Stock Exchange of India Ltd (Scrip Symbol: PFIZER). The communication was signed by Prajeet Nair, Director-Corporate Services & Company Secretary.

In her resignation letter, Ms. Mehta expressed gratitude to the management and colleagues for their support during her tenure with the company. The resignation represents a routine senior management change as the employee transitions to new opportunities outside the organization.

Pfizer Limited , a leading pharmaceutical company in India, has announced strong financial results for the second quarter of fiscal year 2026, demonstrating significant growth across key metrics.

Financial Highlights

Performance Analysis

Pfizer's strong performance in Q2 FY2026 can be attributed to several factors:

1. Revenue Growth: The company's top-line growth of 19.6% suggests robust demand for its pharmaceutical products and effective market strategies.

2. Profitability Improvement: The 19.4% increase in net profit, slightly outpacing revenue growth, indicates effective cost management and operational efficiency.

3. Margin Expansion: The EBITDA margin improvement of 365 basis points to 35.80% demonstrates the company's ability to enhance profitability while growing revenues.

Financial Position

As of September 30, 2025, Pfizer Limited maintains a strong financial position:

Dividend Information

In its Annual General Meeting held on July 21, 2025, Pfizer Limited approved a significant dividend payout for the financial year ended March 31, 2025:

The special dividend commemorates 75 years of Pfizer in India, while the additional special dividend relates to gains from a land and building transfer. The total dividend was paid on July 25, 2025.

Conclusion

Pfizer Limited's Q2 FY2026 results demonstrate the company's ability to deliver strong financial performance in the competitive pharmaceutical sector. With robust revenue growth, improved profitability, and a solid financial position, Pfizer appears well-positioned for continued success in the Indian market.